Teijin Pharma’s Gout Drug Obtains Marketing Authorization In Europe
This article was originally published in PharmAsia News
Executive Summary
Teijin Pharma announced May 7 that its licensee for the EU, Paris-based Ipsen, was granted marketing authorization by the European Commission for TMX-67 (febuxostat) for the treatment of chronic hyperuricemia in gout. Ipsen submitted the application to the EMEA in August 2006 and received a positive opinion this past February. TMX-67 is a non-purine selective inhibitor of xanthine oxidase with a different structure than allopurinol. Ispen will market the drug under the name of Adenuric. (Click here for more - Japanese language)